Introduction: Temodal (TMZ) is an oral alternative to dacarbazine.
Aim(s): The aim of this study was to retrospectively analyze the efficacy and safety of TMZ in patients with metastatic pulmonary carcinoids (mPC).
Materials and methods: 34 patients pathologically reviewed mPC according to the WHO criteria, referred to Gustave Roussy from 1993 to 2014 were included. Treatment was given at a dose of 150 mg/m2/day for 5 days (D1=D28), escalated to 200 mg/m2/day if well tolerated. Disease control rate, according to RECIST at 12 months was the primary endpoint. DCR was compared in patients who received both oxaliplatin-based chemotherapy (O-BC) i.e gemox or folfox, and dacarbazine (TMZ or deticene/DTIC-BC) in a subgroup of 16 patients referred to Gustave Roussy or Hospices Civils of Lyon.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Diana Bello Roufai
Bello Roufai D
, Planchard D
, Walter T
, Berdelou A
, Guigay J
, Souquet P J
, Mercier O
, Malka D
, Hervieu V
, Leboulleux S
, Borget I
, Scoazec J Y
, Lombard-Bohas C
, Ducreux M
, Baudin E
To read results and conclusion, please login ...
Further abstracts you may be interested in